KRW 5610.0
(1.63%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -5.88 Billion KRW | -113.79% |
2022 | 42.65 Billion KRW | -10.21% |
2021 | 47.5 Billion KRW | 52.69% |
2020 | 31.11 Billion KRW | 10980.1% |
2019 | -285.98 Million KRW | -111.65% |
2018 | 2.45 Billion KRW | 106.73% |
2017 | 1.18 Billion KRW | 700.26% |
2016 | 148.36 Million KRW | 303.41% |
2015 | -72.94 Million KRW | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -1.43 Billion KRW | -24.61% |
2024 Q1 | -1.14 Billion KRW | -370.4% |
2023 Q3 | -1.14 Billion KRW | 57.44% |
2023 Q1 | -2.49 Billion KRW | 88.37% |
2023 FY | -5.88 Billion KRW | -113.79% |
2023 Q4 | 425.07 Million KRW | 137.24% |
2023 Q2 | -2.68 Billion KRW | -7.72% |
2022 Q1 | 48.5 Billion KRW | 194.69% |
2022 FY | 42.65 Billion KRW | -10.21% |
2022 Q4 | -21.41 Billion KRW | -1027.17% |
2022 Q3 | 2.3 Billion KRW | -82.58% |
2022 Q2 | 13.25 Billion KRW | -72.67% |
2021 Q1 | 7.33 Billion KRW | 13.86% |
2021 Q2 | 1.32 Billion KRW | -81.95% |
2021 Q3 | 22.39 Billion KRW | 1592.02% |
2021 FY | 47.5 Billion KRW | 52.69% |
2021 Q4 | 16.46 Billion KRW | -26.49% |
2020 Q4 | 6.44 Billion KRW | 135.91% |
2020 Q2 | 22.3 Billion KRW | 470014.73% |
2020 Q1 | 4.74 Million KRW | 102.36% |
2020 FY | 31.11 Billion KRW | 10980.1% |
2020 Q3 | 2.73 Billion KRW | -87.76% |
2019 Q3 | -9.15 Million KRW | -107.57% |
2019 FY | -285.98 Million KRW | -111.65% |
2019 Q4 | -200.88 Million KRW | -2093.42% |
2019 Q2 | 120.91 Million KRW | 54.34% |
2019 Q1 | 78.33 Million KRW | -76.22% |
2018 Q3 | 339.25 Million KRW | 0.0% |
2018 Q4 | 329.39 Million KRW | -2.91% |
2018 FY | 2.45 Billion KRW | 106.73% |
2017 FY | 1.18 Billion KRW | 700.26% |
2016 FY | 148.36 Million KRW | 303.41% |
2015 FY | -72.94 Million KRW | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 219.75 Billion KRW | 102.676% |
InBody Co.,Ltd | 128.11 Billion KRW | 104.59% |
Curexo Inc. | 17.95 Billion KRW | 132.751% |
Seegene, Inc. | 180.07 Billion KRW | 103.266% |
i-SENS, Inc. | 101.04 Billion KRW | 105.82% |
Ray Co., Ltd. | 65.08 Billion KRW | 109.035% |
Gencurix Inc. | 422.03 Million KRW | 1493.46% |
L&C Bio Co., Ltd | 32.52 Billion KRW | 118.08% |